{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:08:55Z","timestamp":1764331735226},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.ejpb.2008.06.018","type":"journal-article","created":{"date-parts":[[2008,7,3]],"date-time":"2008-07-03T11:48:03Z","timestamp":1215085683000},"page":"882-888","source":"Crossref","is-referenced-by-count":8,"title":["In vitro release of propofol and binding capacity with regard to plasma constituents"],"prefix":"10.1016","volume":"70","author":[{"given":"Maximilian","family":"Schicher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margit","family":"Polsinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albin","family":"Hermetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Prassl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2008.06.018_bib1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/00000542-200510000-00026","article-title":"Propofol \u2013 the challenges of formulation","volume":"103","author":"Baker","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejpb.2008.06.018_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2125.1999.00860.x","article-title":"Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics","volume":"47","author":"Mazoit","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2008.06.018_bib3","doi-asserted-by":"crossref","first-page":"7417","DOI":"10.1523\/JNEUROSCI.22-17-07417.2002","article-title":"Structural evidence that propofol stabilizes different GABA(A) receptor states at potentiating and activating concentrations","volume":"22","author":"Williams","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejpb.2008.06.018_bib4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1213\/00000539-199811000-00032","article-title":"The significance of lipoproteins in serum binding variations of propofol","volume":"87","author":"Zamacona","year":"1998","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejpb.2008.06.018_bib5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00228-002-0520-z","article-title":"\u2018In vitro\u2019 binding of propofol to serum lipoproteins in thyroid dysfunction","volume":"58","author":"de la Fuente","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2008.06.018_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2253-5-4","article-title":"Human physiologically based pharmacokinetic model for propofol","volume":"5","author":"Levitt","year":"2005","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.ejpb.2008.06.018_bib7","first-page":"15","article-title":"New formulation of propofol in an LCT\/MCT emulsion","volume":"1","author":"Babl","year":"1995","journal-title":"Eur. Hosp. Pharm."},{"key":"10.1016\/j.ejpb.2008.06.018_bib8","first-page":"472","article-title":"Reducing pain during propofol injection: the role of the solvent","volume":"82","author":"Doenicke","year":"1996","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejpb.2008.06.018_bib9","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2125.1999.00942.x","article-title":"Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan (R)-10 after bolus injection","volume":"47","author":"Knibbe","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2008.06.018_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00044011-200222070-00001","article-title":"Pharmacokinetics of the generic formulation propofol 1% Fresenius in comparison with the original formulation (Disoprivan (R) 1%)","volume":"22","author":"Jungheinrich","year":"2002","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ejpb.2008.06.018_bib11","series-title":"Lipoproteins: Clinical, Biochemistry, Principles, Methods, and Applications","first-page":"23","article-title":"Chemical and physical properties of lipoproteins","author":"Kostner","year":"1989"},{"key":"10.1016\/j.ejpb.2008.06.018_bib12","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0022-2275(20)38583-7","article-title":"Biotinylation of low density lipoproteins via free amino groups without loss of receptor binding activity","volume":"28","author":"Roach","year":"1987","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejpb.2008.06.018_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0005-2760(90)90032-S","article-title":"Biotinyl-high-density lipoproteins as a probe for the determination of high-density lipoprotein turnover in humans","volume":"1043","author":"Daerr","year":"1990","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejpb.2008.06.018_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0378-5173(90)90381-D","article-title":"Drug release from submicronized o\/w emulsion: a new in vitro kinetic evaluation model","volume":"66","author":"Levy","year":"1990","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2008.06.018_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(90)90280-H","article-title":"Drug release from microdisperse systems: a critical review","volume":"58","author":"Washington","year":"1989","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2008.06.018_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0378-5173(89)90062-8","article-title":"Evaluation of non-sink dialysis methods for the measurement of drug release from colloids: effects of drug partition","volume":"56","author":"Washington","year":"1989","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2008.06.018_bib17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/014860710302700158","article-title":"Effects of particle size on blood clearance and tissue uptake of lipid emulsions with different triglyceride compositions","volume":"27","author":"Qi","year":"2003","journal-title":"J. Parenter. Enteral Nutr."},{"key":"10.1016\/j.ejpb.2008.06.018_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/01.mol.0000226110.66942.e8","article-title":"The unique role of apolipoprotein A-I in HDL remodeling and metabolism","volume":"17","author":"Pownall","year":"2006","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ejpb.2008.06.018_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0009-3084(76)90035-9","article-title":"Application of microcalorimetry to the study of lipid\u2013protein interaction","volume":"17","author":"Rosseneu","year":"1976","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.ejpb.2008.06.018_bib20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.5551\/jat.12.240","article-title":"Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000","volume":"12","author":"Arai","year":"2005","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.ejpb.2008.06.018_bib21","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/sj.ijo.0803332","article-title":"Lipoprotein lipase gene S447X polymorphism modulates the relation between central obesity and serum lipids, a twin study","volume":"30","author":"Huang","year":"2006","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ejpb.2008.06.018_bib22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11886-005-0065-8","article-title":"Obesity and lipids","volume":"7","author":"Miller","year":"2005","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.ejpb.2008.06.018_bib23","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1172\/JCI111444","article-title":"Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment","volume":"74","author":"Eisenberg","year":"1984","journal-title":"J. Clin. Invest."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641108002403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641108002403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T22:03:25Z","timestamp":1631484205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641108002403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0939641108002403"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2008.06.018","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}